Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide vs placebo in chemotherapy‑naive metastatic castration‑resistant prostate cancer (China cohort)
CTR20140131Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Started Mar 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20140131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140131.